Rabivax-S — Competitive Intelligence Brief

Rabivax-S (Rabivax-S) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Rabies vaccine. Area: Infectious Disease / Immunology.

marketed Rabies vaccine Rabies virus glycoprotein Infectious Disease / Immunology Biologic

Target snapshot

Rabivax-S (Rabivax-S) — University of Oxford. Rabivax-S is a recombinant rabies virus vaccine that stimulates immune responses against rabies virus through viral glycoprotein antigens.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rabivax-S TARGET	Rabivax-S	University of Oxford	marketed	Rabies vaccine	Rabies virus glycoprotein
Rabies immune globulin (human)	Rabies immune globulin (human)	Sanofi Pasteur, a Sanofi Company	marketed	Passive immunizing agent; immunoglobulin	Rabies virus glycoprotein
HyperRAB	HyperRAB	Bio Products Laboratory	marketed	Rabies immunoglobulin (human)	Rabies virus glycoprotein
Purified Vero Rabies Vaccine	Purified Vero Rabies Vaccine	Sanofi Pasteur, a Sanofi Company	phase 3	Inactivated viral vaccine	Rabies virus glycoprotein
PVRV and pERIG Favirab®	PVRV and pERIG Favirab®	Sanofi Pasteur, a Sanofi Company	phase 3	Monoclonal antibody immunoglobulin (rabies-specific)	Rabies virus glycoprotein
Cell-culture rabies vaccine	Cell-culture rabies vaccine	GlaxoSmithKline	phase 3	Inactivated viral vaccine	Rabies virus glycoprotein
HDCV Comparator	HDCV Comparator	Wilbur Chen, MD, MS	phase 3	Inactivated viral vaccine	Rabies virus glycoprotein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Rabies vaccine class)

1. University of Oxford · 1 drug in this class